SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman to support its novel vaccine platform through accelerated clinical development SpyBiotech has raised $32.5M from leading investors to advance development of its novel “plug and display” vaccine platform technologyBraavos Investment Advisers led the round, joined by new investor...

SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19 OXFORD, United Kingdom, Sept. 08, 2020 (GLOBE NEWSWIRE) -- SpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases, today announces that its...